Abivax completes enrollment for study of ulcerative colitis candidate

Abivax has completed enrollment in a phase 2b induction study for its ulcerative colitis drug candidate ABX464, according to a company press release.The company said they successfully randomly assigned 232 patients ahead of schedule, despite challenges presented by the COVID-19 pandemic. They expect topline results to be available in the second quarter of 2021.“With the financial resources of 84 million euros we secured over the past 6 months, Abivax is able to go full speed in advancing ABX464 into a pivotal phase 2b/3 study in Crohn’s disease and to prepare for the phase 3Read More

Share on facebook
Share on twitter
Share on linkedin